PHASE 1 RANDOMIZED STUDY OF THE STEADY-STATE (SS) EFFECTS OF BEMPEDOIC ACID (BA) ON THE SINGLE-DOSE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC) TABLETS IN HEALTHY FEMALES.

被引：0
作者：
Emery, M. [1 ]
MacDougall, D. [1 ]
Amore, B. [1 ]
McGonigal, J. [1 ]
Hanselman, J. [1 ]
Sasiela, W. [1 ]
机构：
[1] Esper Therapeut, Ann Arbor, MI USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII-002
引用
收藏
页码：S79 / S79
页数：1
相关论文
共 47 条
  • [41] A RANDOMIZED, SINGLE-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE, PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS (PK), AND PHARMACODYNAMICS (PD) OF TAK-272 IN HEALTHY ADULT NON-ELDERLY AND ELDERLY MALE SUBJECTS
    Matsuno, K.
    Tanaka, S.
    Hashimoto, T.
    Nakamichi, H.
    Komura, E.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 265 - +
  • [42] Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase-1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study
    Wang, Yuhao
    Yu, Chao
    Hu, Mengyue
    Wang, Lu
    Chen, Meixia
    Liu, Hanmo
    Wu, Nan
    Hou, Jie
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2025,
  • [43] A PHASE 1, SINGLE ASCENDING DOSE (SAD) STUDY OF FOOD EFFECT AND DRUG-DRUG INTERACTION (DDI) EFFECTS OF PH-MODIFYING AGENTS ON INCB099280 PHARMACOKINETICS (PK), A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR, IN HEALTHY PARTICIPANTS
    Gong, X.
    Cimino, E.
    Leonetti-Whalen, C.
    Wang, P.
    Chen, X.
    Punwani, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S79 - S79
  • [44] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Small Molecule GLP-1 Receptor Agonist (HRS-7535) in Healthy Subjects -A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study
    Wu, Jingying
    Hu, Wei
    Du, Yijun
    Zhang, Qian
    Zhou, Renpeng
    Zhang, Qin
    Qin, Huiling
    Ye, Zi
    Xu, Yimei
    Feng, Sheng
    Shu, Chang
    Shen, Yu
    Fan, Yang
    DIABETES, 2023, 72
  • [45] A Phase 1, Randomized, Open-label, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17, a Proposed, Higher Concentration Biosimilar (100 mg/mL) Adalimumab, in Healthy Subjects
    Keystone, Edward C.
    Furst, Daniel
    Kay, Jonathan
    Choi, EunJin
    Davidson, Antonia
    Bae, Yunju
    Brimhall, Darin
    Lee, SangJoon
    Kim, SungHyun
    Kwak, DaHye
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [46] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study
    Takizawa, Masaomi
    Hatta, Toshifumi
    Iitsuka, Hiromi
    Katashima, Masataka
    Sato, Yuichiro
    Kuroishi, Kentaro
    Nagashima, Hirotaka
    CLINICAL THERAPEUTICS, 2020, 42 (05) : 906 - 923
  • [47] Pharmacokinetics and Safety of CT-P17, a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar, in Comparison with EU-Approved Adalimumab and US-Licensed Adalimumab; Results of a Phase 1, Randomized, Double-blind, Three-arm, Single-dose Study in Healthy Subjects
    Yu, KyungSang
    Jang, Injin
    Lim, HyeongSeok
    Hong, JangHee
    Kim, MinGul
    Park, MinKyu
    Kim, Anhye
    Park, MinSoo
    Chung, JaeYong
    Ghim, JongLyul
    Lee, SeungHwan
    Yoon, SeokKyu
    Kwon, Insun
    Furst, Daniel
    Keystone, Edward C.
    Lee, SangJoon
    Kim, SungHyun
    Bae, Yunju
    Cha, JungBin
    Kang, HyeJin
    Kay, Jonathan
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345